High mobility group box 1 and Dickkopf-related protein 1 as biomarkers of glucose toxicity, atherogenicity, and lower β cell function in patients with type 2 diabetes mellitus.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 9000468 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2292 (Electronic) Linking ISSN: 08977194 NLM ISO Abbreviation: Growth Factors Subsets: MEDLINE

Publication: London : Informa Healthcare
Original Publication: Chur ; New York : Harwood Academic Publishers, 1988-

Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/metabolism ; HMGB1 Protein* ; Hypertension*/complications; Humans ; Glucose ; Biomarkers

Type 2 diabetes mellitus (T2DM) is associated with increased atherogenicity and inflammatory responses, which may be related to high mobility group box 1 (HMGB1) and Dickkopf-related protein 1 (DKK1). The role of HMGB1 and DKK1 in T2DM is examined in association with lipid and insulin profiles. Serum HMGB1 and DKK1 were measured in T2DM with and without hypertension and compared with controls. The results showed that HMGB1 and DKK1 are higher in T2DM irrespective of hypertension. A large part of the variance in the β-cell index and glucose toxicity was explained by the combined effects of HMGB1 and DKK1. In conclusion, both HMGB1 and DKK1 may contribute to increased atherogenicity in T2DM. Moreover, both biomarkers may cause more deficits in β-cell function and increase glucose toxicity leading to the development of more inflammation and diabetic complications. HMGB1 and the Wnt pathways are other drug targets in treating T2DM.

Keywords: Diabetes mellitus; atherogenicity; biomarkers; inflammation; insulin resistance

0 (HMGB1 Protein)
IY9XDZ35W2 (Glucose)
0 (Biomarkers)

Date Created: 20220927 Date Completed: 20221129 Latest Revision: 20230301

20231215

10.1080/08977194.2022.2126317

36165005